City of Hope | Strategic Alliance Partners

August 04, 2023

Erminia Massarelli MD, PhD, MS, discusses efficacy and safety data with the NTRK inhibitors larotrectinib and entrectinib in patients with non–small cell lung cancer harboring NTRK fusions.

August 03, 2023

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

August 03, 2023

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

August 01, 2023

Alexey Danilov, MD, PhD, reviews data from the phase 2 TRANSCEND FL trial investigating lisocabtagene maraleucel and discusses the clinical implications of the results.

August 01, 2023

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

July 28, 2023

Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.

July 27, 2023

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

July 26, 2023

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

July 25, 2023

ASCO has released an update to the guidelines for the practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy.

July 25, 2023

Marwan G. Fakih, MD, reviews data from the phase 3 randomized SUNLIGHT trial investigating trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.

July 24, 2023

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

July 24, 2023

An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.

July 19, 2023

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.

July 19, 2023

In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.

July 17, 2023

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.

July 14, 2023

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.

July 12, 2023

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530.

July 12, 2023

In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.

July 10, 2023

In our fast-moving world where a report of a clinically important trial finding may be simply a 60-second sound bite for both lay and medical communities, it is critical that great care must be taken that reported conclusions are understandable to all, not just the statisticians.

July 06, 2023

The use of prostate stem cell antigen–targeted CAR T-cell therapy was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer.